Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

life.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the data from this study will be fully interpreted or will be submitted to medical meetings in the future. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2006 and in our Quarterly Reports on Form 10-Q. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Rebecca Gregory, Corporate Communications of ImClone SystemsIncorporated, +1-646-638-5058, ; or Media, Madeline Malia,+1-609-252-3347, , or Tony Plohoros, +1-609-252-7938,, or Investors, John Elicker, +1-212-546-3775,, all of Bristol-Myers Squibb media@imclone.com Madeline.Malia@bms.com tony.plohoros@bms.com John.Elicker@bms.com

Web site: http://www.bms.com/http://www.ERBITUX.com/

Ticker Symbol: (NYSE:BMY),(NASDAQ-NMS:IMCL)

Terms and conditions of use apply
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/25/2014)... 2014  Depomed, Inc. (NASDAQ: DEPO ) ... year 2014 financial results after the market closes on Wednesday, ... call beginning at 4:30 pm EDT, 1:30 pm PDT to discuss ... by dialing 877-317-6789 ( United States ) ... available via a live webcast on the investor relations ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Full Service ... as the new Vice President of Business Development. Peter ... years in a number of different business development positions ... These positions were primarily related to business development/sales management ... past 30 years makes him a key and strategic ...
(Date:7/25/2014)... and Tobago , July 25, 2014 /PRNewswire/ ... Trinidad & Tobago Ministry of Health approved the ... that significantly increases the cure rate from Hepatitis ... with the genotype 1 virus. Telaprevir is available ... trade brand INCIVO®. Photo - ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... VRUS ) today announced that it will webcast ... of the Liver (EASL) on Saturday, April 2, 2011 starting ... progress on the programs that are the subject of presentations ... simultaneous webcast of this event via the internet, log on ...
... 25, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... confirmed that it has received a favorable decision from ... related to its ongoing patent challenge in connection with ... to market a generic version of Teva Women,s Health, ...
Cached Medicine Technology:Pharmasset to Webcast an Investor Event From the EASL Meeting 2Pharmasset to Webcast an Investor Event From the EASL Meeting 3Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge 2
(Date:7/25/2014)... The Little Gym of Houston will ... July 27 at Discovery Green in downtown Houston. The ... Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, Bellaire ... “We’re thrilled to be attending and performing at the ... owns the Sugarland-Missouri City location. “We believe in the ...
(Date:7/25/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Ibuprofen and Oxcarbazepine Tablets . ... of Ibuprofen and one lot of Oxcarbazepine Tablets, by American ... packaging. Oxcarbazepine is used for the treatment of certain types ... reason for the recall is that Lot #142588, Expiration Date, ...
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... California Memorial Stadium. With the post-World Cup emotions still rolling ... the 2014 Guinness International Champions Cup have brought eight of ... representing La Liga, English Premier League, Serie A, and Superleague ... players from around the world to 12 American cities and ...
(Date:7/25/2014)... July 25, 2014 On July ... Nuanced Media client and the nation’s number one ... employee handbooks, announced their partnership with TransAct Merchant ... a registered ISO/MSP of Chase Paymentech Solutions, LLC, ... processing industry. Companies that are members of TransAct’s ...
(Date:7/25/2014)... Hastings and Hastings, a ... with regard to personal injury claims, announces free initial ... of legal services for those that have been injured ... or corporation. Free initial consultation services gives clients’ greater ... potential personal injury claim . It also offers ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... N.Y., March 23 You went on a diet. Great. ... keeping the weight off? What are your chances of avoiding ... Chronic Disease recommends that you turn to your doctor and ... measures the concentration of your IgG antibodies against two prevalent ...
... Study Adds to Growing Evidence of B. Infantis 35624 ... A review by researchers at Northwestern University ... , MI) of the utility of probiotics in the ... Bifidobacterium infantis 35624 was the only probiotic strain ...
... Physician-Owned Hospitals, According to New Reports from ... leading provider of managed care market intelligence, ... have traditionally enabled doctors practicing in the ... these regulations may actually yield increasing challenges ...
... for Distinguished Service in the Field of ChemistryEMERYVILLE, ... Alternext: NBY) today announced that world-renowned scientist M. ... Scientific Advisory Board will be the recipient of ... by the American Chemical Society (ACS). Dr. ...
... is One of Three FDA Approvals Spanning Lilly ... and Drug Administration (FDA) has approved a new ... Eli Lilly and Company (NYSE: LLY ... drug approved by the FDA for the acute ...
... PARK, Kan., March 23 According to the National ... recession since December 2007 and nearly half of U.S. ... iconic Oprah Winfrey replaced her annual ,Favorite Things, holiday ... "Thriftiest Holiday Ever!"However, the $200 billion health & wellness ...
Cached Medicine News:Health News:How to Keep the Weight Off? By Taking Gene-Eden, a New Dietary Supplement Based on Dr. Hanan Polansky's Discovery of the Cause of Many Diseases 2Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 2Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 3Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 4Health News:Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy for IBS Symptoms 5Health News:In Texas, Favorable Regulations for Physicians May Backfire in Light of Market Downturn 2Health News:NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award 2Health News:NovaBay Pharmaceuticals' Scientific Advisor Receives American Chemical Society's Highest Award 3Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 2Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 3Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 4Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 5Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 6Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 7Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 8Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 9Health News:FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression 10Health News:Consumers Redefine Value in the Recession: Sauna Sales Prove Preventive Health Is an Essential Investment 2
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... point-of-care device for the qualitative detection of drug ... TOX/See device can detect up to nine of ... 8 minutes and requires only a few drops ... to maximize convenience and ease of use. TOX/See ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
Medicine Products: